Compare Lucid Group Inc (LCID) vs Pfizer Inc (PFE) Price & Performance

Lucid Group (LCID) trades at $7.04, up 0.86% with a neutral technical signal despite recent earnings misses. The company reported Q2 2026 revenue of $405.3 million (beating estimates) but a wider loss of $3.30 per share due to inventory charges. Management is executing a $1.4 billion operational reset focusing on cost reductions, robotaxi partnerships, and delaying the Cosmos EV launch to 2027. Financial metrics show severe challenges with negative gross margins of -96.56% and net income margin of -249.21%.

The outlook remains high-risk with persistent cash burn and competitive pressures, though analyst consensus targets $10.50 representing 49% upside. Key risks include execution of the turnaround plan, EV market demand, and the need for future capital raises. The stock offers speculative potential if cost savings materialize but faces significant fundamental headwinds.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.